Nuvalent, Inc. (NUVL)
NUVL Stock Price Chart
Explore Nuvalent, Inc. interactive price chart. Choose custom timeframes to analyze NUVL price movements and trends.
NUVL Company Profile
Discover essential business fundamentals and corporate details for Nuvalent, Inc. (NUVL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Jul 2021
Employees
162.00
Website
https://www.nuvalent.comCEO
James R. Porter
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
NUVL Financial Timeline
Browse a chronological timeline of Nuvalent, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Nov 2025
EPS estimate is -$1.38.
Earnings released on 7 Aug 2025
EPS came in at -$1.31 falling short of the estimated -$1.27 by -3.15%.
Earnings released on 8 May 2025
EPS came in at -$1.18 falling short of the estimated -$1.14 by -3.51%.
Earnings released on 27 Feb 2025
EPS came in at -$1.05 falling short of the estimated -$1.04 by -0.96%.
Earnings released on 12 Nov 2024
EPS came in at -$1.28 falling short of the estimated -$0.93 by -37.03%.
Earnings released on 8 Aug 2024
EPS came in at -$0.88 falling short of the estimated -$0.76 by -15.79%.
Earnings released on 9 May 2024
EPS came in at -$0.69 falling short of the estimated -$0.67 by -2.99%.
Earnings released on 27 Feb 2024
EPS came in at -$0.62 falling short of the estimated -$0.59 by -5.08%.
Earnings released on 14 Nov 2023
EPS came in at -$0.59 matching the estimated -$0.59.
Earnings released on 10 Aug 2023
EPS came in at -$0.51 surpassing the estimated -$0.53 by +3.77%.
Earnings released on 11 May 2023
EPS came in at -$0.44 surpassing the estimated -$0.51 by +13.73%.
Earnings released on 16 Mar 2023
EPS came in at -$0.49 falling short of the estimated -$0.43 by -13.95%.
Earnings released on 10 Nov 2022
EPS came in at -$0.41 surpassing the estimated -$0.46 by +10.87%.
Earnings released on 10 Aug 2022
EPS came in at -$0.38 surpassing the estimated -$0.43 by +11.63%.
Earnings released on 12 May 2022
EPS came in at -$0.36 surpassing the estimated -$0.40 by +10.00%.
Earnings released on 29 Mar 2022
EPS came in at -$0.36 falling short of the estimated -$0.32 by -12.50%, while revenue for the quarter reached -$2.43M .
Earnings released on 10 Nov 2021
EPS came in at -$0.39 falling short of the estimated -$0.25 by -56.00%.
Earnings released on 8 Sept 2021
EPS came in at -$3.17 falling short of the estimated -$0.19 by -1.57K%.
Earnings released on 30 Jul 2021
EPS came in at -$0.30 .
Earnings released on 31 Dec 2020
EPS came in at -$0.29 .
Earnings released on 30 Sept 2020
EPS came in at -$0.21 .
NUVL Stock Performance
Access detailed NUVL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.